(+)-N,N-Dimethyl-butyl-(2)-amin | 921-04-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (+)-N,N-Dimethyl-butyl-(2)-amin
• 英文别名: (2S)-N,N-dimethylbutan-2-amine
• CAS: 921-04-0；40916-66-3
• 化学式: C₆H₁₅N
• 分子量: 101.192
• InChiKey: USSPHSVODLAWSA-LURJTMIESA-N

物化性质

• 熔点：
  -102.35°C (estimate)
• 沸点：
  93.25°C
• 密度：
  0.7340

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 (S)-(+)-2-氨基丁烷 在 甲酸 作用下， 生成 (+)-N,N-Dimethyl-butyl-(2)-amin
  参考文献：
  名称：

  Photoreduction of aromatic ketones by amines. Studies of quantum yields and mechanism

  摘要：

  DOI：

  10.1021/ja01003a029

文献信息

• 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20150336962A1

  公开（公告）日：2015-11-26

  Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

  这里描述了化合物的公式（00A）及其作为Janus激酶抑制剂的使用方法。
• CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF
  申请人：Matsumoto Takahiro

  公开号：US20100266504A1

  公开（公告）日：2010-10-21

  Provided are a condensed pyridine derivative having a serotonin 5-HT 2C receptor activation action, a prophylactic or therapeutic agent for a lower urinary tract symptom, obesity and/or organ prolapse and the like containing the condensed pyridine derivative, a screening method for a substance that increases leak point pressure upon a rise in the intravesical pressure or a prophylactic or therapeutic drug for stress urinary incontinence, a prophylactic or therapeutic drug for cystoceles or enteroceles, containing a substance that activates serotonin 5-HT 2C receptor, and a method of screening for a therapeutic drug for cystoceles or enteroceles, including increasing an intravesical pressure after bilateral transection of the hypogastric nerve and pudendal nerve of an animal, and measuring a closure response in the urethra, the rectum or the vagina observed at that time. A serotonin 5-HT 2c receptor activator containing a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof.

  提供了一种具有血清素5-HT2C受体激活作用的缩合吡啶衍生物，以及包含该缩合吡啶衍生物的预防或治疗下尿路症状、肥胖和/或器官脱垂等药物，以及增加膀胱内压力时增加泄漏点压力或预防或治疗压力性尿失禁的药物筛选方法，包含激活血清素5-HT2C受体的物质的预防或治疗膀胱脱垂或肠脱垂的药物，以及通过双侧切断动物的会阴神经和耻骨神经后增加膀胱内压力并测量尿道、直肠或阴道在此时观察到的闭合反应的膀胱脱垂或肠脱垂的治疗药物筛选方法。其中包含式的化合物的血清素5-HT2C受体激活剂：式中每个符号如规范中定义的那样，或其盐。
• 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Genentech, Inc.

  公开号：US20160237086A1

  公开（公告）日：2016-08-18

  Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.

  本文描述了化学式(00A)的化合物以及作为Janus激酶抑制剂的使用方法。
• 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3145929B1

  公开（公告）日：2021-01-13
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20170275289A1

  公开（公告）日：2017-09-28

  The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R 1 , R 3 , R 4 , R 5 , and each R e have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.